Neptune Files an Opposition Against Aker's Australian Patent Application

Neptune Files an Opposition Against Aker's Australian Patent Application

LAVAL, Quebec, Nov. 27, 2012 (GLOBE NEWSWIRE) -- Neptune Technologies &
Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX:NTB) announced today that on
November 9, 2012 it filed a Notice of Opposition in Australia against Aker
Biomarine ASA's ("Aker") patent application no. AU2008291978 entitled "New
Method for Making Krill Meal".

Neptune opposes the acceptance of Aker's patent by the Australian Patent
Office ("APO") because it has evidence that the invention claimed in the
application is neither new nor inventive. Neptune will present clear
disclosures in printed publications and patents, published years before Aker`s
patent, that teach exactly what Aker claims in its patent application and
serve as strong prior art against Aker's patent.

This follows Neptune's previous request for re-examination against Aker's
AU2008231570 patent which lead the APO to invalidate Aker's claims to a krill
oil production process for lack of the required novelty and inventive step.
This is in line with Neptune's intellectual property strategy aiming to
reinforce its position as the krill oil innovator and a market leader, in
order to secure the rapidly growing krill oil market and protect its

"Anyone who claims to be free to operate in Australia based on a patent
license from Aker is at risk, as Neptune firmly believes that Aker's patents
and patent applications will eventually be declared invalid by the APO or the
courts, while Neptune's patents will be enforceable," stated Neptune's Chief
Global Strategic Officer, Dr. Tina Sampalis.

The United States Patent and Trademark Office has recently issued a final
rejection for the corresponding patent application in the U.S. to the one
opposed by Neptune in Australia.Interestingly, both the U.S. and European
Patent Offices have not yet granted a patent to Aker for a krill oil
composition and/or for a method to make krill products.

About Neptune Technologies & Bioressources Inc.

Neptune is a biotechnology company engaged primarily in the development and
commercialization of marine-derived omega-3 polyunsaturated fatty acids, or
PUFAs. Neptune has a patented process of extracting oils from Antarctic krill,
which omega-3 PUFAs are then principally sold as bulk oil to Neptune's
distributors who commercialize them under their private label primarily in the
U.S., European and Australian neutraceutical markets. Neptune's lead products,
Neptune Krill Oil (NKO®) and ECOKRILL Oil (EKO™), generally come in capsule
form and serve as a dietary supplement to consumers.

Through its subsidiaries Acasti (TSX-V:APO) and NeuroBio, in which Neptune
respectively holds 57% and 99% of the voting rights, Neptune is also pursuing
opportunities in the medical food and prescription drug markets. Acasti and
NeuroBio respectively focus on the research and development of safe and
therapeutically effective compounds for highly prevalent atherosclerotic
conditions, such as cardiometabolic disorders and cardiovascular diseases, and
for neurodegenerative and inflammation related conditions. Acasti's lead
prescription drug candidate is CaPre®, a purified high omega-3 phospholipid
concentrate derived from Neptune krill oil being developed to address the
prevention and treatment of cardiometabolic disorders, including
hypertriglyceridemia, which is characterized by abnormally high levels of

CONTACT: Neptune Technologies & Bioressources Inc.
         Andre Godin, CFO
         Neptune Technologies & Bioressources Inc.
         Frederic Harland, Director of Finance
         Neptune Technologies & Bioressources Inc.
         Jean-Daniel Belanger,
         Director, Securities and Corporate Affairs
Press spacebar to pause and continue. Press esc to stop.